RISK OF UPPER GASTROINTESTINAL (GI) TRACT EVENTS IN RISEDRONATE AND/OR ALENDRONATE USERS IN THE ERA OF MARKETED GENERIC ALENDRONATE PRODUCTS

被引：0
|
作者：
Ralston, S. H. [1 ]
Kou, T. D. [2 ]
Wick-Urban, B. C. [3 ]
Steinbuch, M. [2 ]
机构：
[1] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Procter & Gamble Pharmaceut Inc, Mason, OH USA
[3] Procter & Gamble Pharmaceut Inc, Schwalbach, Germany
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 28 条
  • [1] Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate
    Ralston, Stuart H.
    Kou, Tzuyung D.
    Wick-Urban, Bettina
    Steinbuch, Michael
    Masud, Tahir
    CALCIFIED TISSUE INTERNATIONAL, 2010, 87 (04) : 298 - 304
  • [2] Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate
    Stuart H. Ralston
    Tzuyung D. Kou
    Bettina Wick-Urban
    Michael Steinbuch
    Tahir Masud
    Calcified Tissue International, 2010, 87 : 298 - 304
  • [3] Erratum to: Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate
    Stuart H. Ralston
    Tzuyung D. Kou
    Bettina Wick-Urban
    Michael Steinbuch
    Tahir Masud
    Calcified Tissue International, 2010, 87 : 550 - 550
  • [4] The risk of upper gastrointestinal (GI) adverse events of patients switching from risedronate to alendronate after the introduction of generic alendronate products in the UK
    Ralston, S. H.
    Kou, T. D.
    Wick-Urban, B. C.
    Steinbuch, M.
    BONE, 2009, 44 : S114 - S115
  • [5] The effect of switching patients from risedronate to alendronate on the risk of upper gastrointestinal (GI) adverse events after the introduction of generic alendronate products in the UK
    Ralston, S. H.
    Kuo, T. D.
    Wick-Urban, B.
    Steinbuch, M.
    BONE, 2009, 44 (02) : S446 - S446
  • [6] Risk of Upper Gastrointestinal Tract Events in Risedronate Users Switched to Alendronate (vol 87, pg 298, 2010)
    Ralston, Stuart H.
    Kou, Tzuyung D.
    Wick-Urban, Bettina
    Steinbuch, Michael
    Masud, Tahir
    CALCIFIED TISSUE INTERNATIONAL, 2010, 87 (06) : 550 - 550
  • [7] RISK OF UPPER GASTROINTESTINAL (GI) ADVERSE EVENTS AMONG PATIENTS SWITCHED FROM RISEDRONATE TO ALENDRONATE
    Ralston, S. H.
    Kou, T. D.
    Wick-Urban, B. C.
    Steinbuch, M.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S273 - S273
  • [8] An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae
    Lanza, F
    Schwartz, H
    Sahba, B
    Malaty, HM
    Musliner, T
    Reyes, R
    Quan, H
    Graham, DY
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (11): : 3112 - 3117
  • [9] Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: A retrospective cohort study
    Kane, S
    Borisov, NN
    Brixner, D
    AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (07): : S216 - S226
  • [10] Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate
    Blumentals, William A.
    Harris, Steven T.
    Cole, Raymond E.
    Huang, Liping
    Silverman, Stuart L.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (04) : 577 - 585
123